Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma

Marloes Nies,1* Mariëlle S. Klein Hesselink,1* Gea A. Huizinga,5,6 Esther Sulkers,5 Adrienne H. Brouwers,2 Johannes G. M. Burgerhof,3 Eveline W. C. M. van Dam,8 Bas Havekes,9 Marry M. van den Heuvel-Eibrink,10 Eleonora P. M. Corssmit,11 Leontien C. M. Kremer,12 Romana T. Netea-Maier,13 Heleen J. H. van der Pal,12,14 Robin P. Peeters,15 John T. M. Plukker,4 Cécile M. Ronckers,12 Hanneke M. van Santen,16 Wim J. E. Tissing,6 Thera P. Links,1 and Gianni Bocca7

1Department of Endocrinology, 2Nuclear Medicine and Molecular Imaging, 3Epidemiology, and 4Surgical Oncology, 5Wenkebach Institute, School of Nursing and Health, Departments of 6Pediatric Oncology and 7Pediatric Endocrinology, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands; 8Department of Internal Medicine, VU University Medical Center, 1007 MB Amsterdam, The Netherlands; 9Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands; 10Department of Pediatric Oncology, Sophia Children’s Hospital, Erasmus Medical Center, 3000 CB Rotterdam, The Netherlands; 11Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; 12Department of Pediatric Oncology, Emma Children’s Hospital, and 13Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; 14Department of Medical Oncology, Academic Medical Center, 1100 DD Amsterdam, The Netherlands; 15Department of Internal Medicine and Rotterdam Thyroid Center, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands; and 16Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands

Context: Little is known about long-term quality of life (QoL) of survivors of pediatric differentiated thyroid carcinoma. Therefore, this study aimed to evaluate generic health-related QoL (HRQoL), fatigue, anxiety, and depression in these survivors compared with matched controls, and to evaluate thyroid cancer–specific HRQoL in survivors only.

Design: Survivors diagnosed between 1970 and 2013 at age ≤18 years, were included. Exclusion criteria were a follow-up <5 years, attained age <18 years, or diagnosis of DTC as a second malignant neoplasm (SMN). Controls were matched by age, sex, and socioeconomic status. Survivors and controls were asked to complete 3 questionnaires [Short-Form 36 (HRQoL), Multidimensional Fatigue Inventory 20 (fatigue), and Hospital Anxiety and Depression Scale (anxiety/depression)]. Survivors completed a thyroid cancer–specific HRQoL questionnaire.

Results: Sixty-seven survivors and 56 controls. Median age of survivors at evaluation was 34.2 years (range, 18.8 to 61.7). Median follow-up was 17.8 years (range, 5.0 to 44.7). On most QoL subscales, scores of survivors and controls did not differ significantly. However, survivors had more physical problems (P = 0.031), role limitations due to physical problems (P = 0.021), and mental fatigue (P = 0.016) than controls. Some thyroid cancer–specific complaints (e.g., sensory complaints and chilliness) were present in survivors. Unemployment and more extensive disease or treatment characteristics were most frequently associated with worse QoL.
The diagnosis and treatment of childhood cancer constitute a major life event that may influence psychosocial functioning and quality of life (QoL) long after initial treatment has been completed. Pediatric differentiated thyroid carcinoma (DTC) is a rare malignancy with an excellent survival rate (1, 2). The incidence of this disease is rising (3, 4). At present there is an increased focus on the long-term consequences of this disease and its treatment. After initial treatment, which most often consists of a total thyroidectomy followed by radioactive iodine (131-I) administration, life-long follow-up is initiated (5). Moreover, about a third of the pediatric DTC survivors in The Netherlands have postoperative complications, including permanent hypoparathyroidism, which also require medical support (2). Both hypothyroidism and hypoparathyroidism have been described as negatively affecting the QoL of DTC survivors (6, 7).

The available data on QoL in survivors of pediatric DTC are limited. Most studies evaluate QoL in survivors of adolescent and adult DTC. QoL in survivors of adolescent DTC was found to be normal compared with control groups (8, 9). Survivors of adult DTC reported lower health-related QoL (HRQoL) and higher levels of generic HRQoL, fatigue, anxiety, and depression compared with healthy controls (5, 10–12). For DTC survivors, thyroid cancer–specific complaints may arise after treatment and during follow-up. Most long-term survivors of adult DTC with a median follow-up period of 9.6 years experienced disease-specific symptoms (13). In survivors of pediatric DTC, thyroid cancer–specific complaints have not yet been evaluated.

QoL studies performed in survivors of other childhood cancers showed conflicting results. QoL varied from no differences to lower QoL in survivors, compared with a control or comparison group; this may be explained by the differences in specific clinical characteristics of the different types of cancers in which this has been studied (14–20).

Several specific survivor characteristics may influence QoL during follow-up. QoL may improve in survivors of adult DTC after a longer time following diagnosis, especially ≥5 years after diagnosis (10, 21). Employment and a higher educational level were found to be associated with better QoL in survivors of adult DTC (12, 21, 22). Young adult survivors reported other thyroid cancer–specific complaints than did older survivors. For example, young adult survivors reported more scar complaints, but less voice complaints (22). QoL in DTC survivors seems to be independent of thyrotropin (TSH) levels (8, 10).

So far, information is limited on long-term QoL in survivors of pediatric DTC. Therefore, the first aim of our study was to evaluate QoL by means of the self-reported levels of generic HRQoL, fatigue, anxiety, and depression in adult survivors of pediatric DTC compared with those of matched controls. The second aim was to evaluate whether long-term generic HRQoL, fatigue, anxiety, depression, and thyroid cancer–specific HRQoL were associated with survivor, tumor, treatment, or follow-up characteristics.

### Materials and Methods

#### Survivors

Adult survivors of pediatric DTC who participated in a nationwide follow-up study were asked to participate in this substudy (2). Inclusion criteria for the nationwide study were: diagnosis of DTC between January 1970 and December 2013 at the age of ≥18 years, and treatment in The Netherlands [as described earlier (2)]. Exclusion criteria for this substudy were: follow-up <5 years after diagnosis, attained age <18 years, diagnosis of DTC as a second malignant neoplasm, lack of command of the Dutch language, and 131-I administration within 3 months before evaluation.

#### Controls

To include controls, survivors were asked to approach 1 or 2 persons of similar sex and age (±5 years of the survivor’s age) at time of follow-up. The only exclusion criterion for controls was having a medical history of malignancy. Preferably, peers were included as controls, trying to match on socioeconomic status. If this was not possible, siblings were allowed to be matched controls.

#### Participants

All survivors and controls gave informed consent before participating in the study. The Institutional Review Board of the University Medical Center Groningen approved the study on behalf of all participating institutions.

#### Medical data

- Data on survivor and tumor characteristics (tumor–node–metastasis classification, histology, and age at diagnosis), treatment (surgical complications, i.e., hypoparathyroidism and recurrent laryngeal nerve injury, and cumulative 131-I dose), and follow-up (follow-up time; outcome, i.e., remission, recurrence, or persistent disease; and level of TSH suppression during follow-up) were retrieved from medical records.

Conclusions: Overall, long-term QoL in survivors of pediatric DTC was normal. Survivors experienced mild impairment of QoL in some domains (physical problems, mental fatigue, and various thyroid cancer–specific complaints). Factors possibly affecting QoL need further exploration. (J Clin Endocrinol Metab 102: 1218–1226, 2017)
marital status, job status, and level of education were retrieved from a questionnaire.

QoL assessment

Generic HRQoL, fatigue, anxiety, and depression questionnaires were assessed for survivors and controls. The thyroid cancer-specific HRQoL questionnaire was assessed for survivors only. The questionnaires delineated below were used to assess QoL.

Short-Form 36

The Short-Form 36 (SF-36) (23) is a 36-item health survey, validated for the Dutch population (24). This questionnaire measures self-reported HRQoL on 8 domains: physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores of domains are presented on a scale from 0 to 100. A higher score indicates better HRQoL. The scores of the 8 subscales were converted into the physical and mental component scales by means of the algorithm of Ware and Kosinski (25), based on Dutch norms (24). An example of a question in the SF-36 questionnaire is, “In general, would you say your health is…?” Possible answers are “poor,” “fair,” “good,” “very good,” “excellent.”

Multidimensional Fatigue Inventory 20

The Multidimensional Fatigue Inventory 20 (MFI-20) (26) self-report instrument was designed to measure fatigue. Fatigue is scored on 5 domains: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The MFI-20 was proven to be valid for the Dutch population (26). The total score, ranging from 20 to 100 (higher scores indicating more fatigue), is calculated as the sum of the 5 domains, and each domain (range, 4 to 20) is the sum of 4 items. Each domain includes 4 items on a 1- to 5-point scale ranging from “no, that is not true” to “yes, that is true.” An example of an item is “thinking requires effort.”

Hospital Anxiety and Depression Scale

The Hospital Anxiety and Depression Scale (HADS) (27) is a 14-item self-assessment scale measuring levels of depression and anxiety. This questionnaire has been validated for Dutch subjects (28). Scores on subscales range from 0 to 21. Scores for the total scale can range from 0 to 42. A higher score indicates a higher level of anxiety and/or depression. Answers can be given on a 4-point Likert scale. For example, for “I feel tense or wound up,” possible answers are “not at all,” “from time to time, occasionally,” “a lot of the time,” or “most of the time.”

Thyroid cancer–specific HRQoL

The thyroid cancer–specific HRQoL (THYCA-QoL) (29) questionnaire was designed to assess treatment- and cancer-specific side effects of thyroid cancer. For a time frame dealing with the previous week (except in the case of the sexual interest item, which refers to the previous 4 weeks), items can be scored on a 4-point scale ranging from 1 (“not at all”) to 4 (“very much”). Items are summarized and translated into 7 scales (neuromuscular, voice, concentration, sympathetic, throat/mouth, psychological, and sensory problems) and 6 single items (problems with scar, felt chilly, tingling hands/feet, gained weight, headache, interest in sex). Scales range from 0 to 100. A higher score on this scale indicates more complaints. An example of a question in the THYCA-QoL questionnaire is “Have you had a dry mouth?”

Statistical analysis

Characteristics of survivors included in the QoL study were compared with characteristics of the excluded survivors from the nationwide study and to the eligible, but not included, survivors in the QoL study. Characteristics of survivors and controls were compared to evaluate whether controls were a good comparison group for the included survivors. Scores on HRQoL, fatigue, anxiety, and depression of survivors and matched controls were compared. Scores on thyroid cancer-specific HRQoL were analyzed using descriptive statistics. Associations between survivor, tumor, treatment, and follow-up characteristics and scores on QoL were assessed. Single items of the THYCA-QoL were dichotomized (not at all = no; a little; quite a bit; and very much = yes) before testing these associations. Comparisons were made using χ² tests or a Fisher’s exact test (if >20% of the cells had an expected count of <5) in case of categorical variables. Mann–Whitney U and Kruskal–Wallis tests were performed because normality and homogeneity assumptions of dependent variables had been violated. For analyses of possible correlations between 2 variables with ordinal scales, the Spearman rank correlation coefficient was used. The TSH level for each year of follow-up was expressed as the geometric mean of the observed TSH values during that year, as published previously (30).

Missing or unknown values were excluded (listwise deletion) from analyses or, in case of the 4 questionnaires, imputed using questionnaire-specific guidelines. For SF-36 and the THYCA-QoL, scores were imputed when ≤50% values of the scores for this subscale were missing. For MFI-20 and HADS, scores were imputed when ≥2 values of the subscale were not missing. When these criteria were not met, survivors or controls were excluded from analyses of the relevant subscale. IBM SPSS Statistics for Windows version 23 (IBM, Armonk, NY) was used for statistical analyses. Differences were considered statistically significant at P < 0.05. To adjust for the multiple testing, a significance level of 1% (P < 0.01) was used for the tested associations between survivor, tumor, treatment, and follow-up characteristics and QoL.

Results

Characteristics of survivors of pediatric DTC and matched controls

Out of 105 survivors participating in the nationwide study (2), 75 survivors were eligible for this long-term QoL substudy, 67 of whom (89.3%) agreed to participate. Eight survivors eligible for the QoL study were not included (Fig. 1). As expected, survivors of the nationwide study, excluded for the QoL study, and participating survivors in the QoL study differed in age at evaluation (median 19.1 vs 34.2 years, respectively; P < 0.001) and follow-up duration (median 2.8 vs 17.8 years, respectively; P < 0.001). For all other survivor, tumor, treatment, or follow-up characteristics, survivors of the 3 groups did not differ (Supplemental Table 1).

Table 1 shows the demographic characteristics of the survivors and their matched controls. Median age of survivors at evaluation was 34.2 years (range, 18.8 to 61.7). Most survivors were female (86.6%), were married or in a relationship (64.2%), and had a paid job or were full-time students (91.0%). Tumor, treatment, and follow-up
characteristics of survivors are shown in Supplemental Table 1. Survivors had a median follow-up time of 17.8 years (range, 5.0 to 44.7) after diagnosis. All survivors underwent a total thyroidectomy and 131-I was administered to 97.0%. Of the survivors, 82.1% remained in remission during follow-up. Ten percent had recurrence of the disease and 7% had persistent disease.

The 67 survivors gathered 59 controls. Three controls were not included because matching criteria were not met. The survivor and control groups did not differ significantly with respect to sex, age, marital status, employment/education, nationality, or completed education (Table 1). Almost 14% of the controls were siblings of the survivors.

QoL in adult survivors of pediatric DTC (vs matched controls)

Table 2 summarizes self-reported QoL measurements in survivors and controls. For the subscales of the questionnaires, survivors had significantly lower scores on physical functioning and role limitations due to physical problems as compared with controls ($P = 0.031$ and $P = 0.021$; lower scores represent worse HRQoL) [Fig. 2(A) and 2(B)]. Mental fatigue scores were significantly higher in survivors ($P = 0.012$; higher scores represent more fatigue) [Fig. 2(C)]. Scores on the remaining SF-36 and MFI-20 subscales and all HADS subscales did not differ significantly between survivors and controls. In 12 out of 15 subscales on

### Table 1. Characteristics of Adult Survivors of Pediatric DTC and Matched Controls

<table>
<thead>
<tr>
<th></th>
<th>Survivors (n = 67)</th>
<th>Controls (n = 56)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>58 (86.6)</td>
<td>49 (87.5)</td>
<td>0.878$^a$</td>
</tr>
<tr>
<td>Male</td>
<td>9 (13.4)</td>
<td>7 (12.5)</td>
<td></td>
</tr>
<tr>
<td>Age at evaluation, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>34.2 (18.8–61.7)</td>
<td>34.0 (19.4–60.2)</td>
<td>0.431$^b$</td>
</tr>
<tr>
<td>Age at diagnosis, y</td>
<td></td>
<td></td>
<td>n.a.</td>
</tr>
<tr>
<td>Median (range)</td>
<td>15.8 (7.9–18.8)</td>
<td>—</td>
<td>n.a.</td>
</tr>
<tr>
<td>Follow up duration, y</td>
<td></td>
<td></td>
<td>n.a.</td>
</tr>
<tr>
<td>Median (range)</td>
<td>17.8 (5.0–44.7)</td>
<td>—</td>
<td>n.a.</td>
</tr>
<tr>
<td>Nationality, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutch</td>
<td>67 (100)</td>
<td>56 (100)</td>
<td>0.129$^a$</td>
</tr>
<tr>
<td>Marital status, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relationship</td>
<td>43 (64.2)</td>
<td>43 (76.8)</td>
<td></td>
</tr>
<tr>
<td>No relationship</td>
<td>24 (35.8)</td>
<td>13 (23.2)</td>
<td></td>
</tr>
<tr>
<td>Completed education, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low level</td>
<td>16 (23.9)</td>
<td>6 (10.7)</td>
<td>0.128$^a$</td>
</tr>
<tr>
<td>Medium level</td>
<td>25 (37.3)</td>
<td>21 (37.5)</td>
<td></td>
</tr>
<tr>
<td>High level</td>
<td>26 (38.8)</td>
<td>29 (51.8)</td>
<td></td>
</tr>
<tr>
<td>Employment, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employed or full-time student</td>
<td>61 (91.0)</td>
<td>50 (89.3)</td>
<td>0.743$^a$</td>
</tr>
<tr>
<td>Unemployed and no full-time student</td>
<td>6 (9.0)</td>
<td>6 (10.7)</td>
<td></td>
</tr>
<tr>
<td>Relationship with survivor, n (%)</td>
<td></td>
<td></td>
<td>n.a.</td>
</tr>
<tr>
<td>Peer</td>
<td>—</td>
<td>48 (85.7)</td>
<td></td>
</tr>
<tr>
<td>Sibling</td>
<td>—</td>
<td>8 (14.3)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: n.a., not applicable.

$^a$χ² Test.

$^b$Mann–Whitney U test.
generic HRQoL, fatigue, anxiety, and depression, the interquartile range of scores was larger for survivors than for controls; for none of the 15 subscales was the interquartile range of scores for controls larger than that for the survivors. For the component scales, scores on the physical component scale were significantly lower in survivors compared with controls ($P = 0.024$; lower scores represent worse HRQoL). Scores of other summary scales (mental component scale, total MFI-20, and total HADS scores) did not differ significantly between survivors and controls. Scores of survivors with a second malignant neoplasm (SMN) are reported in Supplemental Table 2. Three survivors developed a SMN after DTC. Scores of QoL of the 2 women diagnosed with breast cancer were similar compared with the survivors that were not diagnosed with a SMN. For 1 woman diagnosed with a high-grade cervical intraepithelial neoplasia, QoL scores were lower compared with the survivors that were not diagnosed with a SMN after DTC. Siblings of survivors did not differ significantly from nonsiblings in scores on questionnaires (data not shown). For thyroid cancer–specific QoL, scores of

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Survivors $\text{(n = 67)}$</th>
<th>Controls $\text{(n = 56)}$</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SF-36, median (p25, p75)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical functioning</td>
<td>95 (85, 100)$^a$</td>
<td>100 (95, 100)$^b$</td>
<td>0.031$^c$</td>
</tr>
<tr>
<td>Role limitations due to physical problems</td>
<td>100 (75, 100)$^a$</td>
<td>100 (100, 100)$^b$</td>
<td>0.021$^c$</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>84 (72, 100)$^b$</td>
<td>100 (74, 100)$^d$</td>
<td>0.104</td>
</tr>
<tr>
<td>Social functioning</td>
<td>88 (63, 100)</td>
<td>100 (81, 100)</td>
<td>0.065</td>
</tr>
<tr>
<td>Mental health</td>
<td>84 (72, 92)$^a$</td>
<td>84 (76, 92)</td>
<td>0.723</td>
</tr>
<tr>
<td>Role limitations due to emotional problems</td>
<td>100 (67, 100)$^a$</td>
<td>100 (67, 100)$^b$</td>
<td>0.711</td>
</tr>
<tr>
<td>General health perceptions</td>
<td>72 (57, 87)$^a$</td>
<td>77 (67, 89)</td>
<td>0.231</td>
</tr>
<tr>
<td>Vitality</td>
<td>65 (50, 78)$^a$</td>
<td>70 (60, 80)</td>
<td>0.194</td>
</tr>
<tr>
<td>Mental component summary scale</td>
<td>54 (41, 56)$^a$</td>
<td>53 (47, 56)$^b$</td>
<td>0.961</td>
</tr>
<tr>
<td>Physical component summary scale</td>
<td>53 (47, 57)$^a$</td>
<td>57 (53, 59)$^b$</td>
<td>0.024$^c$</td>
</tr>
<tr>
<td><strong>MFI-20, median (p25, p75)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General fatigue</td>
<td>10 (8, 15)</td>
<td>9 (5, 12)</td>
<td>0.075</td>
</tr>
<tr>
<td>Physical fatigue</td>
<td>8 (5, 12)</td>
<td>6 (4, 10)</td>
<td>0.083</td>
</tr>
<tr>
<td>Reduced activity</td>
<td>8 (5, 11)</td>
<td>8 (5, 11)</td>
<td>0.613</td>
</tr>
<tr>
<td>Reduced motivation</td>
<td>6 (4, 9)</td>
<td>6 (4, 9)</td>
<td>0.879</td>
</tr>
<tr>
<td>Mental fatigue</td>
<td>9 (5, 15)</td>
<td>7 (4, 10)</td>
<td>0.012$^c$</td>
</tr>
<tr>
<td>Total</td>
<td>41 (31, 57)</td>
<td>36 (27, 54)</td>
<td>0.129</td>
</tr>
<tr>
<td><strong>HADS, median (p25, p75)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>4 (2, 9)</td>
<td>3 (2, 6)</td>
<td>0.317</td>
</tr>
<tr>
<td>Depression</td>
<td>1 (0, 4)</td>
<td>1 (0, 3)</td>
<td>0.964</td>
</tr>
<tr>
<td>Total</td>
<td>6 (2, 11)</td>
<td>4 (3, 9)</td>
<td>0.392</td>
</tr>
</tbody>
</table>

For SF-36, higher scores indicate a better HRQoL; subscales range from 0 to 100. For MFI-20, higher scores indicate more fatigue; subscales range from 4 to 20; the total scale ranges from 20 to 100. For HADS, higher scores indicate higher levels of anxiety and/or depression; subscales range from 0 to 21; the total scale ranges from 0 to 42. For THYCA-QoL, a higher score indicates more symptoms; subscales range from 0 to 100.

$a_n = 66$ because 1 survivor filled in the questionnaire erroneously.

$b_n = 54$ because 2 controls filled in the questionnaire erroneously.

$cP < 0.05$. Scores on the SF-36, MFI-20, and HADS were compared using the Mann–Whitney U test.

$d_n = 53$ because 3 controls filled in the questionnaire erroneously.

$e_n = 65$ because 2 survivors filled in the questionnaire erroneously.
survivors are shown in Table 2 and Fig. 2(D). Most frequently reported were neuromuscular, throat/mouth, psychological, and sensory complaints, feeling chilly, and headache.

Characteristics associated with QoL in adult survivors of pediatric DTC

Characteristics that were possibly associated with QoL in adult survivors of pediatric DTC are shown in Supplemental Table 3. Male survivors reported higher levels of reduced motivation and more depression than did females \((P = 0.007\) and \(P = 0.009\)). Unemployment was associated with lower scores on physical functioning and the physical component scale \((P = 0.005\) and \(P = 0.003\)) and higher levels of general fatigue, physical fatigue, and total fatigue \((P = 0.009, P = 0.009,\) and \(P = 0.004,\) respectively).

Treatment with a higher cumulative dose of 131-I was associated with more complaints of headache \((P = 0.006)\). Survivors with recurrent or persistent disease and survivors with a higher level of TSH suppression reported more complaints about the scars in their necks \((P < 0.001\) and \(P = 0.002)\).

Marital status at follow-up, educational level, age at follow-up, all tumor characteristics \((i.e.,\) age at diagnosis, tumor–node–metastasis stage, and histology), surgical complications \((permanent hypoparathyroidism and recurrent laryngeal nerve injury),\) and follow-up duration showed no significant associations with QoL (HRQoL, fatigue, anxiety, depression, and/or thyroid cancer-specific HRQoL).

Discussion

In the present study, we focus on long-term QoL in adult survivors of pediatric DTC, and our results show overall normal HRQoL, fatigue, anxiety, and depression in these survivors compared with matched controls. This normal QoL is similar to that found in studies performed in survivors of adolescent DTC \((8, 9)\). Although survivors reported more physical problems, role limitations due to physical problems, and mental fatigue, the overall scores of survivors on these domains were still within the normal range. Thyroid cancer-specific complaints were present in some survivors, but most survivors reported relatively few or no complaints \([Table 2; Fig. 2(D)]\). Another reflection of the normal QoL of the survivors is their full participation in society, exemplified in most of these survivors by high employment and relationship rates and an educational level comparable to matched controls. Thereby, most \((88\%)\) of the survivors reported to have an interest in sex.

Remarkably, the overall QoL in survivors of pediatric DTC seems to be better than the QoL of survivors diagnosed with DTC at older ages. HRQoL, fatigue,
anxiety, and depression were reported as worse in both short- and long-term survivor studies in adult DTC compared with controls (10, 11). Additionally, survivors of (young) adult DTC seem to experience more severe thyroid cancer–specific complaints than do survivors of pediatric DTC (5, 13, 22).

Although overall QoL is normal in pediatric DTC survivors compared with controls, physical problems seemed to be relatively more prominent in the survivor group compared with controls. The impaired physical functioning observed in survivors of pediatric DTC has been described previously in other childhood cancer survivors (18, 19). Also in adult DTC survivors, the largest differences in scores between survivors and the general population were observed for physical complaints and complaints of fatigue (11).

Besides physical obstacles, survivors in the present study experienced mental constraints, in particular mental fatigue, entailing the inability to stay concentrated. Husson et al. (5) proposed that (mental) fatigue in survivors of (adult) DTC might be due to a suboptimal TSH level suppression target or could otherwise be explained by the presence of cancer-related fatigue (31). The present data provided no support for a possible relationship between TSH levels and fatigue, which is consistent with findings in DTC survivors diagnosed at older ages (8, 10).

Normal anxiety and depression levels as we found in the survivors of pediatric DTC were similar to the reported similar levels of emotional distress found in survivors of other childhood cancers (e.g., acute lymphatic leukemia, renal tumor, non-Hodgkin lymphoma, and other types of cancer) and controls (32).

Survivors reported neuromuscular, throat/mouth, psychological, and sensory problems to be most present in the symptom scale items. Headache and feeling chilly were reported most frequently in the single items. Complaints most often reported in survivors of adult DTC were sympathetic complaints, neuromuscular complaints, and complaints of fatigue (13). Physicians underestimate the incidence of several thyroid cancer–specific complaints in survivors (21). For example, although 40% of the survivors reported voice problems, for only 15% of the survivors, recurrent laryngeal nerve injury was reported in their medical records (Supplemental Table 1). Because only 3 survivors were diagnosed with a SMN after DTC (Supplemental Table 2), general conclusions regarding QoL in this specific group of survivors cannot be drawn.

QoL is more variable in survivors compared with controls, as shown by the wider distribution toward worse QoL in survivors [Fig. 2(A–C)]. It would be of great value to be able to portend QoL (variability) based on predictors. Therefore, the present study evaluated whether long-term generic HRQoL, fatigue, anxiety, depression, and thyroid cancer–specific HRQoL were associated with survivor, tumor, treatment, or follow-up characteristics. Of all possible predictors of QoL, unemployment was most frequently associated with worse QoL on many domains. However, the retrospective design of the study does not allow us to make statements regarding the causality of this impairment. This means that employment could influence QoL or vice versa. Socioeconomic factors could play a role in the level of QoL, as has been described previously in studies evaluating QoL in survivors of adult DTC (21, 22). Additionally, we found evidence for a more impaired QoL among survivors undergoing more extensive treatment or survivors with a more extended disease. Survivors with a worse outcome may report more complaints due to their more active disease and treatment. Lower QoL in female survivors of DTC compared with male survivors has been reported by several authors (21, 22). However, owing to the limited number of male survivors in the present study, conclusions regarding associations between sex and QoL could not be drawn. Adverse late effects on physical functioning have been described after administration of 131-I to survivors of adult DTC (33, 34). An association between worse QoL and higher doses of 131-I in survivors of adult DTC has previously been described (35). The present data on survivors of pediatric DTC also show an association between higher cumulative doses of 131-I and worse QoL. In contrast, QoL in survivors of pediatric DTC was shown to be independent of other tumor or treatment characteristics, which confirms findings of studies in survivors of adult DTC (10, 21). Survivors of adult DTC showed an increasing QoL >5 years after diagnosis (21). The normal QoL in the present survivors may be explained by their long-term follow-up, but the present results do not confirm this hypothesis: a longer follow-up period was not associated with better QoL.

The present study has both strengths and limitations. This study considers the QoL of adult survivors of both pediatric and adolescent DTC. Moreover, survivors were compared with sex-, age-, and socioeconomic-matched controls. Because of the cross-sectional design of the study ≥5 years after diagnosis, short-term QoL was not evaluated. Because pediatric DTC is uncommon, gathering a larger group of survivors is difficult. Owing to nonnormally distributed data and the limited number of survivors included in this study, multivariable regression or stratified analysis was not feasible. To make more conclusive statements, international collaboration in prospective studies assessing QoL in pediatric DTC survivors is urgently needed. Moreover, to identify characteristics that predict QoL, longitudinal prospective studies would be more appropriate.

Finally, the results of this study were based only on quantitative data. Combining quantitative and qualitative
elements to assess QoL in survivors of pediatric DTC could help to evaluate perceived physical and mental limitations and parameters that could in turn predict QoL more clearly; such methodology has also been applied in studies of survivors of adult DTC (36).

To identify vulnerable childhood cancer survivors early and offer them the care they need, regular measurement of QoL parameters should be implemented during follow-up. This is in accordance with Dutch evidence-based guidelines for follow-up of childhood cancer survivors (37). Additionally, measurements at baseline and during treatment should also be performed to evaluate individual alterations in QoL. In our opinion, follow-up regarding monitoring QoL is necessary in survivors of pediatric DTC.

In conclusion, this study shows that, in general, long-term adult survivors of pediatric DTC function well in society, with relatively good HRQoL and levels of fatigue, anxiety, and depression that are similar to matched controls. Various thyroid cancer–specific complaints were present (e.g., sensory complaints, headache, and chilliness), but mostly in mild forms. However, physical problems and mental fatigue seemed to be relatively more prominent in the survivor group compared with controls. Thereby, scores on QoL in survivors are widespread, indicating individual differences between survivors. Factors most frequently associated with worse QoL were unemployment and more extensive disease or treatment characteristics. These predictors will have to be further explored in future studies. We recommend evaluating changes in the QoL of individual pediatric DTC patients from diagnosis to long-term follow-up, using a prospective screening program to be able to provide early and individualized care to prevent long-term alterations in QoL.

Acknowledgments

We are grateful to our colleagues in The Netherlands for referring patients for this study. We thank the registration teams of the Comprehensive Cancer Centers for the collection of data for the Netherlands Cancer Registry, as well as the scientific staff of the Netherlands Cancer Registry. We also thank Heleen Maurice-Stam for sharing expert opinion with us during analysis of the SF-36.

Address all correspondence and requests for reprints to: Thera P. Links, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Endocrinology, AA31, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: t.p.links@umcg.nl.

This work was supported by Stichting Kinderen Kankervrij (The Netherlands, Foundation Children Cancer-Free, Project 81). C.M.R. is supported by the Dutch Cancer Society.

Clinical trial registry: Netherlands Trial Registry 3448 (registered 3 June 2012).

Disclosure Summary: The authors have nothing to disclose.

References


